Revenue segments as reported by the company.

Product sales

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development

Selling, general and administrative

Other

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Amgen

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amgen reports robust Q4 results, navigates pricing challenges for growth

Amgen's Q4 earnings call highlighted strong performance, innovative products, and strategic acquisitions driving growth. Challenges in pricing strategies and market dynamics require careful navigation. Opportunities in promising data, asset advancements, and access strategies position Amgen for future success.

Amgen reports robust Q1 performance, eyes growth in Asia-Pacific

Amgen's Q1 2023 earnings call highlighted strong performance, innovative R&D focus, and growth in key markets like Asia-Pacific.
Despite challenges with inventory issues and pricing dynamics, the company remains optimistic about long-term growth opportunities and biosimilar competitiveness.
Opportunities lie in addressing complex disorders like obesity, expanding market presence, and driving growth in key product franchises.
Overall, Amgen's strategic focus on performance, international expansion, and pipeline advancements positions the company for sustained growth and innovation.

Amgen reports robust Q2 earnings, eyes growth through strategic acquisitions

Amgen's strong Q2 performance, robust sales growth, and strategic acquisitions position the company for continued success.
While facing challenges in competitive markets and potential legal risks, Amgen's focus on innovation and portfolio expansion presents growth opportunities.
With a solid financial outlook, increased R&D investments, and a focus on shareholder returns, Amgen remains well-positioned for future growth.
Updates on key products, positive trial results, and strategic initiatives underscore Amgen's commitment to advancing healthcare and driving value creation.

Amgen reports revenue and earnings growth, eyes AI for innovation

Amgen's Q3 performance showed revenue and earnings growth, driven by strong global volume and record sales for key medicines. The company's pipeline progress and strategic focus on R&D highlight a commitment to innovation and future growth. While challenges exist around acquisition integration and market competition, Amgen is poised for continued success through the end of the decade and beyond.

Amgen reports record sales in Q4 2023, eyes rare diseases

Amgen's Q4 2023 performance was robust, driven by record sales and strategic acquisitions.
Despite short-term challenges like tax payments impacting cash flow, the company remains confident in its long-term growth trajectory.
Opportunities lie in expanding the rare disease portfolio, advancing R&D initiatives, and exploring new therapeutic areas.
Overall, Amgen's strong financials, diverse pipeline, and focus on innovation position it well for sustained growth and global impact.

Amgen reports strong Q1 growth, eyes new markets and innovations

Amgen's Q1 2024 performance reflects strong sales growth, financial resilience, and continued momentum in key product segments, positioning the company for future success.
Despite challenges in competitive differentiation, product launches, and regulatory complexities, Amgen's strategic strengths in innovation, manufacturing, and market expansion offer a solid foundation for growth.
The company's focus on addressing unmet medical needs, exploring new therapeutic areas, and advancing pipeline candidates underscores its commitment to driving patient impact and capturing market opportunities.
With a robust financial outlook, ongoing Phase III trials, and a proactive approach to product development, Amgen is well-positioned to achieve its revenue targets, drive innovation, and deliver value to shareholders.

Amgen reports strong Q2 earnings, eyes growth in diverse markets

Amgen's Q2 2024 earnings call highlighted robust revenue growth, strong sales performance, and promising pipeline developments across various therapeutic areas.
While facing challenges in market dynamics and product differentiation, Amgen's strategic focus on rare diseases and innovative therapies positions it well for future growth.
With a clear outlook on capital allocation, continued expansion in endocrinology, and opportunities in the obesity market, Amgen remains poised for sustained success.

Amgen reports strong Q3 earnings and outlines growth strategies

Amgen's Q3 2024 earnings call highlighted robust financial performance, progress in pipeline development, and strategic initiatives for future growth. With a strong revenue outlook and focus on innovation, Amgen remains well-positioned in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

While Amgen's (AMGN) growth drugs like Prolia & Xgeva may do well, biosimilar competition and slowdown in sales of mature products are likely to put pressure on second-quarter sales.

Can Newer Drugs Help Amgen (AMGN) Beat on Earnings in Q2?

Allergan

Gilead Sciences

Incyte

Regeneron Pharmaceuticals

We take a look at the overall drug/biotech sector's performance and five stocks that are poised to beat on earnings in the second quarter of 2019.

5 Drug/Biotech Stocks Set to Beat Earnings Estimates in Q2

Novartis

Novartis (NYSE:NVS) and Amgen (NASDAQ:AMGN) announced the failure of a candidate drug treatment for Alzheimer's disease.

More bad news for Alzheimer's patients

Amgen (AMGN) and Novartis (NVS) discontinue two Alzheimer's disease studies. Alzheimer's has always been a highly challenging area with many studies failing.

Amgen & Novartis' Alzheimer Studies End in Another Failure

A drug to treat Alzheimer's disease is increasingly proving elusive, despite billions of dollars spent on research and development.

Novartis, Amgen Scrap Pivotal Study Of Alzheimer's Prevention Drug

Amgen Inc. AMGN, -2.34% and Novartis AG NVS, -1.15% announced Thursday afternoon that they will discontinue a study into a potential Alzheimer's disease prevention therapy after patients in the study showed worsening conditions.

Amgen and Novartis drop Alzheimer's-prevention study after patients worsened

Alexion Pharma

Biogen

Celgene

MannKind

The short interest data are out for the most recent settlement date, June 28. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big potential upside and big potential downside.

Short Sellers Run for Cover From Major Biotechs

Baxter

CVS Health

DaVita

Fresenius Medical Care

Dialysis stocks move north after Trump signs an executive order designed to reform the nation's kidney treatment industry.

Trump's Order on Kidney Care Lifts These Dialysis Stocks

Abbott Labs

Johnson & Johnson

Eli Lilly

Medtronic

Merck

Pfizer

Thermo Fisher Scientific

UnitedHealth Group

How big does a company's market cap need to be to make the top 10 list of healthcare stocks? $111 billion.

The 10 Biggest Healthcare Stocks

Novo Nordisk

Sanofi

Teva Pharmaceutical

The recent ruling by a federal court against the Trump regime's decree to disclose the price labels of drugs in TV adverts resumes the spotlight on drug pricing.

Court Ruling Topples Trump Order, No Price Display in TV Ads

AbbVie

Bristol-Myers

With key drugs losing exclusivity, key drug makers are poised to face deep trouble since their sales are mostly dependent on a single drug.

Will Patent Woes Boost Pharma Stock Megamergers Further?

A federal judge on Monday blocked the Trump administration from implementing a new rule that would force pharmaceutical companies to include the wholesale prices of their drugs in television advertising.

US judge halts Trump administration rule requiring drug prices in TV ads

The biotech's shares perked up for two unrelated reasons last month.

Here's Why Amgen Stock Gained 10% in June

Rogers

Learn how the marriage of science and technology is changing the world of medicine and creating some of the largest multinational biotechnology corporations.

The Top 10 Biotechnology Companies (JNJ, ROG.VX)

Alphabet

Lockheed Martin

Tanger Factory Outlet Centers

AT&T

Investors who are feeling a little gutsy should consider these 5 stocks to buy to take advantage of the market's weariness right now.

5 Stocks to Buy as You Rebalance Your Portfolio

Editas Medicine

Vertex Pharmaceuticals

SPDR S&P Biotech ETF

Seven simple steps to improving your chances of success in this part of the market.

How to Invest in Biotech Stocks

Exelixis

Novocure

These three businesses are a great way for investors to support the war on cancer.

3 Cancer-Treatment Stocks to Buy

AstraZeneca

According to the GuruFocus All-in-One Screener, the following companies look cheap since they are trading with low price-sales ratios.

Stocks With Low Price-Sales Ratios

The CHMP provides an unfavorable feedback to Amgen's (AMGN) marketing application for Evenity to treat severe osteoporosis in postmenopausal women with risk of fracture.

Amgen's Osteoporosis Drug Evenity Gets Adverse CHMP View

Roche Holding AG

Here's how these biotech stocks became the biggest on the market -- and how their future prospects look.

The 10 Biggest Biotech Stocks

President Trump issues an executive order that would pressure insurers, doctors and other providers to disclose more information about health-care prices.

Trump to issue executive order to increase transparency in health-care prices

Biotech giant Amgen is putting up the money to fund three research projects in partnership with the University of Washington’s Institute for Protein Design (IPD).

Amgen and University of Washington’s Institute for Protein Design team up to build better cancer drugs

If you’re looking for the next big thing in investing, these three down but not out biotech stocks are the way to go.

3 Large-Cap Biotech Stocks to Buy for Massive Gains

Abeona Therapeutics

Savara

Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.

Biotech Stock Roundup: Amgen Gets FDA Nod for Kanjinti, Regeneron Presents Data

There has been a flurry of M&A deal announcements this year in the drug industry. Here we discuss three big drug/biotech companies, which may make the next M&A move.

News for Amgen Stock (AMGN)